GenScript announced today that it received FDA emergency use authorization (EUA) for its cPass SARS-CoV-2 neutralizing antibody detection kit. Piscataway, N.J.-based GenScript touts its test as the first commercially available diagnostic for specifically detecting neutralizing antibodies without the use of live virus. It measures the presence of neutralizing antibodies in any sample, both in patients […]